Updated July 2026 · 8 min read

Cefepime for ICU Nurses 2026 — Broad Coverage With a Quiet Neuro Risk

Part of the ICU Emergencies Hub — browse every related guide in one place.

Cefepime (Maxipime) is a fourth-generation cephalosporin that has become the go-to gram-negative partner for vancomycin in many ICUs — partly because it sidesteps the kidney-injury signal that dogs the vancomycin-Zosyn combination. It is a clean, broad drug, but it carries one under-recognized danger every ICU nurse should be able to spot: a neurotoxicity that hides as delirium, especially when the kidneys aren't clearing it.

What it covers and where it fits

Cefepime is a fourth-generation cephalosporin with broad activity: it hits many gram-negative rods including Pseudomonas aeruginosa, retains good gram-positive coverage against methicillin-sensitive organisms, and is more stable against certain beta-lactamases than earlier cephalosporins. It is used for hospital- and ventilator-associated pneumonia, febrile neutropenia, complicated urinary and intra-abdominal infections, and as the gram-negative backbone of empiric sepsis therapy. Like the other broad beta-lactams, it does not cover MRSA (so it pairs with vancomycin) and does not cover atypicals or, on its own, some resistant gram-negatives.

Cefepime-induced neurotoxicity: the thing to actually remember

This is the reason cefepime gets its own article. Cefepime crosses into the central nervous system and, at high concentrations, is neuro-excitatory. When levels build up — almost always because the dose was not reduced for impaired renal function — patients can develop cefepime-induced neurotoxicity (CIN): new confusion, agitation, decreased consciousness, myoclonus (sudden muscle jerks), encephalopathy, and even non-convulsive status epilepticus that an EEG has to catch.

Renal dosing is the whole safety story

Cefepime is cleared by the kidneys, so dose and interval must be reduced as renal function falls, and adjusted around dialysis. The overwhelming majority of neurotoxicity cases trace back to a dose that wasn't adjusted for the patient's creatinine clearance. As the nurse, one of your highest-value checks is simply confirming that the ordered cefepime dose is congruent with today's renal function — kidney function in the ICU changes fast, and a dose that was right on admission can be too high two days into an AKI.

Why many units pick cefepime over Zosyn

When a septic patient needs both MRSA and gram-negative coverage, the gram-negative choice is often cefepime or piperacillin-tazobactam (Zosyn). Because the vancomycin-plus-Zosyn combination has been repeatedly associated with acute kidney injury, many ICUs now prefer vancomycin-plus-cefepime when renal risk is a concern — trading Zosyn's anaerobic coverage (which isn't always needed) for a cleaner kidney profile. The tradeoff is that you accept cefepime's neuro risk and its thinner anaerobic coverage, so the choice is patient-specific: an intra-abdominal source may still favor Zosyn or an added anaerobic agent.

Related: Vancomycin guide · Piperacillin-tazobactam (Zosyn) guide · ICU sepsis protocol · Levetiracetam (Keppra) guide

Educational content for licensed clinicians. Always follow your facility's pharmacy dosing protocol and provider orders. Not medical advice.